Vortioxetine: A Review in Cognitive Dysfunction in Depression
Abstract
Vortioxetine (Brintellix®; Trintellix®), a generally efficacious and well tolerated antidepressant agent, is approved in the EU and USA for the treatment of major depressive disorder (MDD) in adults. The drug has a distinctive pharmacological profile (combining inhibition of the serotonin transporter with modulation of multiple serotonin receptors) and has been shown to enhance cognitive performance in various animal models and clinical trials. Across three large, placebo-controlled studies in adults with recurrent MDD, short-term treatment with vortioxetine almost always resulted in statistically significant and clinically meaningful improvements in performance on two objective measures (the Digit Symbol Substitution Test and Rey Auditory Verbal Learning Test) that together cover a broad range of cognitive domains, including executive function, attention, processing speed, learning and memory. Vortioxetine also significantly improved a subjective measure of cognitive function (the Perceived Deficits Questionnaire) and an objective measure of functional capacity (the University of San Diego performance-based skills assessment). In general, the beneficial effects of vortioxetine on these measures were largely independent of its effect on improving depressive symptoms. Based on the available data, therefore, vortioxetine is a useful treatment option in patients with MDD where impaired cognitive function is apparent.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The multimodal antidepressants like Vortioxetine have an independent effect on improving cognition.
“In addition to the antidepressant effects, the multimodal antidepressants like Vortioxetine have an independent effect on improving cognition,41”
Robust evidence exists regarding the use of vortioxetine to treat mood-related symptoms of depression and slowed processing speed, and it is the only FDA-cleared psychotropic medication to treat both.
“Robust evidence exists regarding the use of vortioxetine to treat mood-related symptoms of depression and slowed processing speed (Bennabi et al., 2019;Frampton, 2016;Harrison et al., 2016;Mahableshwarkar et al., 2015;McIntyre et al., 2014), and it is the only FDA-cleared psychotropic medication to treat both.”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Frampton, 2016
Cites
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547 · see citing works
(2023) · Elsevier eBooks · doi:10.1016/c2021-0-02248-3 · Cited by 542 · see citing works
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445 · cited 13× · see citing works
“Like vortioxetine, duloxetine significantly improved performance on the RAVLT (Table 1); overall, the cognitive effects of this SNRI, in particular in ELDERLY, were consistent with those seen in an earlier trial in elderly patients with recurrent MDD [25].”
BackgroundMethodInfluentialLam, R. W. M., Kennedy, S. H., McIntyre, R. S., & Khullar, A. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405901206 · Cited by 444 · see citing works
McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433 · see citing works
Raskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.900 · Cited by 329 · see citing works
Rosenblat, J. D., Kakar, R., & McIntyre, R. S. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv082 · Cited by 315 · cited 1× · see citing works
“Some conventional antidepressants, including SSRIs and SNRIs, may to a degree improve cognitive deficits associated with MDD, although the majority of supporting studies have been limited by small sample sizes, absence of placebo controls, a lack of pre-specification of cognition as a primary outcome, and an inability…”
BackgroundMahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307 · see citing works
Cognitive remission: a novel objective for the treatment of major depression?
Bortolato, B., Miskowiak, K. W., Köhler, C. A., Maes, M., Fernandes, B. S., Berk, M., & Carvalho, A. F. (2016) · BMC Medicine · doi:10.1186/s12916-016-0560-3 · Cited by 252 · see citing works
Baldwin, D. S., Chrones, L., Florea, I., Nielsen, R. Z., Nomikos, G. G., Palo, W. A., & Reines, E. H. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116628440 · Cited by 187 · see citing works
McIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw055 · Cited by 185 · see citing works
Pehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161 · see citing works
McIntyre, R. S., Xiao, H. X., Syeda, K., Vinberg, M., Carvalho, A. F., Mansur, R. B., Maruschak, N., & Cha, D. S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0263-x · Cited by 145 · see citing works
Citrome, L. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12350 · Cited by 140 · see citing works
Leiser, S. C., Li, Y., Pehrson, A. L., Dale, E., Smagin, G. N., & Sánchez, C. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn500340j · Cited by 110 · see citing works
Cognitive Effects of Pharmacotherapy for Major Depressive Disorder: A Systematic Review
Keefe, R. S. E., McClintock, S. M., Roth, R. M., Doraiswamy, P. M., Tiger, S., & Madhoo, M. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08609 · Cited by 107 · see citing works
Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder
McIntyre, R. S., Florea, I., Tonnoir, B., Loft, H., Lam, R. W., & Christensen, M. C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10744 · Cited by 100 · see citing works
Vortioxetine: a New Treatment for Major Depressive Disorder
Connolly, K. R., & Thase, M. E. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1133588 · Cited by 90 · see citing works
Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
Alvarez, E., Artigas, F., & Perez, V. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41387 · Cited by 84 · see citing works
Treating to target in major depressive disorder: response to remission to functional recovery
McIntyre, R. S., Lee, Y. L., & Mansur, R. B. (2015) · CNS Spectrums · doi:10.1017/s1092852915000826 · Cited by 83 · see citing works
Dugan, A. M., Parrott, J. M., Redus, L., Hensler, J. G., & O’Connor, J. C. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv089 · Cited by 61 · see citing works
Al-Sukhni, M., Maruschak, N. A., & McIntyre, R. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1046836 · Cited by 58 · see citing works
Multi-modality: a new approach for the treatment of major depressive disorder
Richelson, E. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001605 · Cited by 49 · see citing works
Vortioxetine: A Review of Its Use in Major Depressive Disorder
Garnock-Jones, K. P. (2014) · CNS Drugs · doi:10.1007/s40263-014-0195-x · Cited by 48 · see citing works
Vortioxetine for the treatment of major depressive disorder
Tritschler, L., Felice, D., Colle, R., Guilloux, J., Corruble, E., Gardier, A. M., & David, D. J. P. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.950655 · Cited by 21 · see citing works
Harvey, P. D., Jacobson, W., Zhong, W., Nomikos, G. G., Christensen, M. C., Olsen, C. K., & Merikle, E. P. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.014 · Cited by 19 · see citing works
Browning, M. D., Smith, J., Conen, S., Smallman, R. P., Buchbjerg, J. K., Larsen, K. G., Olsen, C. K., Christensen, S. R., Dawson, G. R., Deakin, W. F., et al. (2015) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(15)30385-0 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
<p>Cognitive impairment in depression: recent advances and novel treatments</p>
Perini, G., Cotta Ramusino, M., Sinforiani, E., Bernini, S., Petrachi, R., & Costa, A. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199746 · Cited by 384 · see citing works
Vortioxetine exerts anti‐inflammatory and immunomodulatory effects on human monocytes/macrophages
Talmon, M., Rossi, S., Pastore, A., Cattaneo, C. I., Brunelleschi, S., & Fresu, L. G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14074 · Cited by 75 · see citing works
Linking peripheral IL-6, IL-1β and hypocretin-1 with cognitive impairment from major depression
Jin, K., Lü, J., Yu, Z., Shen, Z., Li, H., Mou, T., Xu, Y., & Huang, M. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.08.024 · Cited by 73 · see citing works
Colwell, M., Tagomori, H., Chapman, S., Gillespie, A. L., Cowen, P. J., Harmer, C. J., & Murphy, S. E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02249-6 · Cited by 63 · see citing works
Treatment-Resistant Bipolar Depression: Therapeutic Trends, Challenges and Future Directions
Elsayed, O. H., Ercis, M., Pahwa, M., & Singh, B. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s273503 · Cited by 67 · see citing works
Depression, obstructive sleep apnea and psychosocial health
McFarlane, S. I. (2017) · Sleep Medicine and Disorders International Journal · doi:10.15406/smdij.2017.01.00012 · Cited by 58 · see citing works
Novel treatment options in depression and psychosis
Češková, E., & Šilhán, P. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s157475 · Cited by 56 · see citing works
Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention
Wang, Y., Meng, W., Liu, Z., An, Q., & Hu, X. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.1046692 · Cited by 49 · see citing works
Nathoo, N., & Mackie, A. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.10.004 · Cited by 45 · see citing works
Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models
Stamoula, Ε., Siafis, S., Dardalas, I., Ainatzoglou, A., Matsas, A., Athanasiadis, T., Sardeli, C., Stamoulas, K., & Papazisis, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.677879 · Cited by 44 · see citing works
Adamo, D., Pecoraro, G., Coppola, N., Calabria, E., Aria, M., & Mignogna, M. D. (2020) · Oral Diseases · doi:10.1111/odi.13602 · Cited by 41 · see citing works
Vortioxetina: una nueva alternativa en el trastorno depresivo mayor
Salagre, E., Grande, I., Solé, B., Sánchez‐Moreno, J., & Vieta, E. (2017) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2017.06.006 · Cited by 40 · see citing works
Gilmour, G., Porcelli, S., Bertaina‐Anglade, V., Arce, E., Dukart, J., Hayen, A., Lobo, A., López‐Antón, R., Pich, E. M., Pemberton, D. J., et al. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.025 · Cited by 37 · see citing works
Fiorillo, A., Carpiniello, B., Giorgi, S. D., Pia, S. L., Maina, G., Sampogna, G., Spina, E., Tortorella, A. A. V., & Vita, A. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00493 · Cited by 35 · see citing works
Meinert, S. L., Nowack, N., Grotegerd, D., Repple, J., Winter, N. R., Abheiden, I., Enneking, V., Lemke, H., Waltemate, L., Stein, F., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01330-8 · Cited by 34 · see citing works
Peripheral and central hearing impairment and their relationship with cognition: a review
Nixon, G., Sarant, J. Z., & Tomlin, D. (2019) · International Journal of Audiology · doi:10.1080/14992027.2019.1591644 · Cited by 32 · see citing works
Santos‐García, D., Losada, M. G. A., Hernando, I. C., Cabo, I., Baña, R. M. Y., Redondo, R. A., González, J. M. P., Bartolomé, C. C., Painceiras, M. J. F., Alvarado, M. C. Í., et al. (2022) · Brain Sciences · doi:10.3390/brainsci12111466 · Cited by 31 · see citing works
The effect of acupuncture on depression and its correlation with metabolic alterations
Li, W., Sun, M., Yin, X., Lao, L., Kuang, Z., & Xu, S. (2020) · Medicine · doi:10.1097/md.0000000000022752 · Cited by 31 · see citing works
Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update
Adamo, D., Calabria, E., Coppola, N., Pecoraro, G., & Mignogna, M. D. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211034320 · Cited by 32 · see citing works
Hossain, R., Al-Khafaji, K., Khan, R. A., Sarkar, C. K., Islam, M. S., Dey, D., Jain, D., Faria, F., Akbor, R., Atolanı, O., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14080721 · Cited by 30 · see citing works
Vortioxetine: A new alternative for the treatment of major depressive disorder
Salagre, E., Grande, I., Solé, B., Sánchez‐Moreno, J., & Vieta, E. (2018) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.02.005 · Cited by 28 · see citing works
Zadeh, E. M., Bayanati, S., Ziafat, K., Rezaei, F., Mesgarpour, B., & Akhondzadeh, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120909416 · Cited by 29 · see citing works
Alboni, S., Benatti, C., Colliva, C., Radighieri, G., Blom, J. M. C., Brunello, N., & Tascedda, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603979 · Cited by 28 · see citing works
Giakoumatos, C. I., & Osser, D. N. (2019) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000197 · Cited by 27 · see citing works
Lü, J., Jin, K., Jiao, J., Liu, R., Mou, T., Chen, B., Zhang, Z., Jiang, C., Zhao, H., Wang, Z., et al. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13510 · Cited by 25 · see citing works
Chen, F., Danladi, J., Ardalan, M., Elfving, B., Müller, H. K., Wegener, G., Sánchez, C., & Nyengaard, J. R. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy022 · Cited by 24 · see citing works
Crisanti, C., Enrico, P., Fiorentini, A., Delvecchio, G., & Brambilla, P. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.119 · Cited by 22 · see citing works
Guo, Z., Tang, X., Zhong, S., Chen, G., Chen, P., Chen, C., Chen, R., Huang, L., Jia, Y., & Wang, Y. (2025) · Depression and Anxiety · doi:10.1155/da/1990117 · Cited by 20 · see citing works
Wang, Y., Gu, J., Liu, L., Liu, Y., Tang, W., Ji, C.-H., Guan, W., Zhao, X., Sun, Y., Xu, D., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.673221 · Cited by 20 · see citing works
Pharmacological management of depression in patients with multiple sclerosis
Carta, M. G., Paribello, P., Anastasia, A., Berardis, D. D., Nardi, A. E., & Fornaro, M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1516207 · Cited by 21 · see citing works
Frameworking memory and serotonergic markers
Meneses, A. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0079 · Cited by 19 · see citing works
Duan, L. N., Gao, Y., Shao, X., Tian, C., Fu, C., & Zhu, G. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00647 · Cited by 19 · see citing works
Effects of Vortioxetine on depression model rats and expression of BDNF and Trk B in hippocampus
Sun, B., Lv, Y., Xu, H., Qi, C., Li, C., & Liu, P. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9026 · Cited by 19 · see citing works
C–S Coupling of DNA-Conjugated Aryl Iodides for DNA-Encoded Chemical Library Synthesis
Ji, Y., Dai, D., Luo, H., Shen, S., Fan, J., Wang, Z., Chen, M., Wan, J., Li, J., Ma, H., et al. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00076 · Cited by 18 · see citing works
Diagnostic conversion from unipolar to bipolar affective disorder–A population-based study
Jo, Y. T., Joo, S. W., Kim, H., Ahn, S., Choi, Y. J., Choi, W., Park, S. Y., & Lee, J. S. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.01.082 · Cited by 17 · see citing works
Copper-mediated C H thiolation of (hetero)arenes using weakly coordinating directing group
Wu, P., Cheng, T.-J., Lin, H., Xu, H., & Dai, H. (2020) · Tetrahedron Letters · doi:10.1016/j.tetlet.2020.152062 · Cited by 16 · see citing works
Chen, X., Hu, N., Wang, Y., & Gao, X. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.103729 · Cited by 15 · see citing works
Elmarasi, M., & Fuehrlein, B. (2023) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2023.100392 · Cited by 14 · see citing works
Gao, L., & Zhang, X.-R. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131847 · Cited by 12 · see citing works
Koire, A. M., Joffe, H., & Buckley, R. F. (2022) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000339 · Cited by 13 · see citing works
Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism
Felice, D., Guilloux, J., Pehrson, A. L., Li, Y., Mendez‐David, I., Gardier, A. M., Sánchez, C., & David, D. J. P. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00204 · Cited by 12 · see citing works
Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism—In Vitro Study
Ľupták, M., Fišar, Z., & Hroudová, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213824 · Cited by 12 · see citing works
Pyrosulfite-Involved Synthesis of Sulfides by Palladium-Catalyzed Decarboxylative Couplings
Li, X., Wei, B., Gong, Y., Li, C., Liu, X., Liu, B., Li, Q., & Ban, S. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c00840 · Cited by 10 · see citing works
Vicent-Gil, M., Raventós, B., Martínez, E. D. M., González-Simarro, S., Martínez‐Arán, A., Bonnín, C. D. M., Trujols, J., Pérez‐Blanco, J., de Diego-Adeliño, J., Puigdemont, D., et al. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2117-4 · Cited by 10 · see citing works
Wei, Y., Xu, X., Guo, Q., Zhao, S., Qiu, Y., Wang, D., Yu, W., Liu, Y., & Wang, K. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.024 · Cited by 9 · see citing works
de Cates, A. N., Martens, M., Wright, L. C., Gibson, D., Spitz, G., van Praag, C. G., Suri, S., Cowen, P. J., Murphy, S. E., & Harmer, C. J. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.03.014 · Cited by 9 · see citing works
Manna, C. K., Ranjan, R., Kumar, P., Ahmad, S., & Nath, S. (2023) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_160_23 · Cited by 9 · see citing works
Cognitive Decline and Its Associated Factors in Patients with Major Depressive Disorder
Latiff, H. Z. A., Ariaratnam, S., Shuib, N., & Isa, M. R. (2023) · Healthcare · doi:10.3390/healthcare11070950 · Cited by 9 · see citing works
Chen, W., Maimaitituerxun, R., Xiang, J., Xie, Y., Xiao, F., Wu, X., Chen, L., Yang, J., Liu, A., & Dai, W. (2024) · Psychiatry Investigation · doi:10.30773/pi.2024.0024 · Cited by 8 · see citing works
Inhibitory mechanism of vortioxetine on CYP450 enzymes in human and rat liver microsomes
Zhan, Y., Wang, A., Yu, Y., Chen, J., Xu, X., Nie, J., & Lin, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1199548 · Cited by 8 · see citing works
Nikolič, M., Viktorin, V., Zach, P., Tylš, F., Dudysová, D., Janků, K., Kopřivová, J., Kuchař, M., Brunovský, M., Horáček, J., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.04.019 · Cited by 8 · see citing works
Liu, X., Liu, R., Sun, Y., Wang, H., Wang, H., Wang, T., Ma, Y., Li, X., Wang, Q., Su, Y., et al. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01848-9 · Cited by 7 · see citing works
Smajdor, J., Zambrzycki, M., Paczosa‐Bator, B., & Piech, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314555 · Cited by 7 · see citing works
Yücel, N. T., Kandemir, Ü., Üçel, U. İ., Özkay, Ü. D., & Can, Ö. D. (2023) · Biomedicines · doi:10.3390/biomedicines11041137 · Cited by 6 · see citing works
Memory and attention deficit in chronic migraine
Владимировна, Л. Н., Filatova, E. G., & Osipova, D. V. (2018) · Neuromuscular Diseases · doi:10.17650/2222-8721-2018-8-2-10-16 · Cited by 6 · see citing works
Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition
Johnson, C. R., Kangas, B. D., Jutkiewicz, E. M., Winger, G. D., Bergman, J., Coop, A., & Woods, J. H. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000337 · Cited by 6 · see citing works
Xiang, Z., Xiao, P., Wang, H., Zhu, K., Jiang, Q., Feng, Y., Xiao, H., & Song, R. (2025) · BMC Psychology · doi:10.1186/s40359-025-02593-4 · Cited by 5 · see citing works
Disturbances of affective cognition in mood disorders
Chen, J., Wang, Z., Li, Z., Peng, D., & Fang, Y. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1898-2 · Cited by 4 · see citing works
Ye, X., Xu, P., Jiao, J., Zhao, H., Jin, K., Zhang, S., Pan, F., Chen, J., Jiang, H., Hu, J., et al. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s491768 · Cited by 3 · see citing works
Kotov, S. V., Валентиновна, И. Е., & Egorova, Y. V. (2020) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-0-0- · Cited by 3 · see citing works
Antidepressant Treatment of Depression in the Elderly: Efficacy and Safety Considerations
Norman, T. R. (2021) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2104108 · Cited by 3 · see citing works
The clinical utility of newer antidepressant agents: Understanding the role in management of MDD
Waters, K. (2022) · Mental Health Clinician · doi:10.9740/mhc.2022.10.309 · Cited by 3 · see citing works
Zaky, D. A., Mehny, K. A., Abdelrahman, S. S. M., El-Yamany, M. F., & Kamel, A. S. E. D. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176869 · Cited by 3 · see citing works
Carrillo, P., Rey, R., Padovan, C., Herrmann, M., & Dorey, J. (2022) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000627 · Cited by 3 · see citing works
Rucka, K., & Talarowska, M. E. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19116473 · Cited by 4 · see citing works
Wang, X. P., Ma, X., Long, Y., & Wu, G. (2023) · Aging Medicine · doi:10.1002/agm2.12268 · Cited by 3 · see citing works
Minhas, F. A., Rana, R. Z., Hamdani, S. U., & Rana, M. H. (2021) · Journal of Pakistan Psychiatric Society · doi:10.63050/jpps.18.01.87 · Cited by 3 · see citing works
Hutnyan, M., & McClintock, S. M. (2025) · Transcranial Magnetic Stimulation · doi:10.1016/j.transm.2025.100088 · Cited by 2 · see citing works
Chokka, P. R., Hammer-Helmich, L., Schmidt, S. N., Hubert, M., Reines, E. H., & Grande, I. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2503976 · Cited by 2 · see citing works
Chen, F., He, G., Liu, Y., Zhang, X., Yan, Y., Yan, P., Tian, P., Ye, J., Feng, H., & Li, H. (2025) · Geriatric Nursing · doi:10.1016/j.gerinurse.2025.103402 · Cited by 2 · see citing works
Yineleyici Majör Depresif Bozuklukta Yürütücü İşlevler ve Çalışma Belleğinin Rolü
Çebioğlu, T., & Kafadar, H. (2024) · Türk Psikoloji Dergisi · doi:10.31828/turkpsikoloji.1351431 · Cited by 1 · see citing works
Zheng, J., Tian, Y., Cheng, J., Hu, Z., Zhang, J., Yang, F., Li, P., Jiang, Z., Gong, X., Hou, Q., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118198 · Cited by 1 · see citing works
Efficacy and adverse effect profile of vortioxetine in major depressive disorder: A meta-analysis
Vijayan, S., Ramanathan, B., Mohan, R., Venkatesan, V., Selvaraj, A., & Coumaravelou, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251375106 · Cited by 1 · see citing works
5-HT7 Receptors: New Horizons in the Therapy of Neuropsychiatric and Neurodegenerative Diseases
Rodnyy, A. Y., & Naumenko, V. S. (2025) · Neurochemical Journal · doi:10.1134/s1819712425700333 · Cited by 1 · see citing works
Treatment of depressive disorder with cognitive dysfunction
Češková, E. (2017) · Psychiatrie pro praxi · doi:10.36290/psy.2017.011 · Cited by 1 · see citing works
Novel treatment possibilities in depression and schizophrenia
Češková, E. (2018) · Psychiatrie pro praxi · doi:10.36290/psy.2018.013 · Cited by 1 · see citing works
Cognitive dysfunction: An important feature of major depressive disorder
Duan, D.-X., Li, X., Yang, L., Wang, W., & Zhu, H. (2023) · Neurons and Neurological Disorders · doi:10.58489/2836-8851/011 · Cited by 1 · see citing works
Metal-and Oxidant-Free Electrochemical Synthesis of Aryl Sulfides
Wang, X., Chen, C., Shi, H., Zhang, G., Tang, Y., Zhang, C.-G., Wu, M., & Feng, S. (2021) · Journal of The Electrochemical Society · doi:10.1149/1945-7111/abdc61 · Cited by 1 · see citing works
Pharmacotherapy of cognitive dysfunction in depressive disorder
Češková, E. (2018) · Neurologie pro praxi · doi:10.36290/neu.2018.057
Lü, J., Jin, K., Jiao, J., Liu, R., Mou, T., Chen, B., Zhang, Z., Jiang, C., Zhao, H., Wang, Z., et al. (2022) · medRxiv · doi:10.1101/2022.06.19.22276593
Depression in Older Adults - A Review
Zhou, K., Tan, S. Y., Arroyo, S. P., & Lim, S. C. (2023) · Neurology and Neuroscience · doi:10.33425/2692-7918.1044
Xie, M., Xu, H., Zhu, L., Cai, T., & Shen, R. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11327-y
Zhu, Z., Yang, J., Dai, D., Zhang, L., Zhang, Y., Yin, X., Cai, Y., Li, H., & Tao, W. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07612-7
Vortioxetine: A comprehensive profile
Anwar, Z., Sabir, S., Sheraz, M. A., & Ahmed, S. (2025) · Profiles of drug substances, excipients, and related methodology · doi:10.1016/bs.podrm.2025.12.003
Xie, M., Zhan, Z., Xu, Y., Wu, Y., Chen, J., Cai, T., & Shen, R. (2025) · Sustainable Chemistry and Pharmacy · doi:10.1016/j.scp.2025.102307
Xin, L.-M., Fan, H.-Z., Lin, J., Yan, F., Yu, X. H., Su, Y. G., & Si, T. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122147
Çetinkaya, A., Demirkol, M. E., & Avcı, A. O. (2026) · Konuralp Tıp Dergisi · doi:10.18521/ktd.1866798
Lustyk, K., Jagielska, A., Sałaciak, K., Dudzik, P., Soren, A., Konwar, J., Żelaszczyk, D., Marona, H., Crouzier, L., Meunier, J., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118454
Targeting depression: Pharmacological mechanisms and therapeutic targets
Wang, H., Dong, S., Liu, S., Lai, K., & Chen, N. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109121
Liu, Y., Tan, Y.-F., & Hashimoto, K. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179414
- Authors
- Frampton, J. E.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Frampton, James E.
- ORCID
- Frampton, James E.
- Venue
- Drugs
- Published
- 2016-11
- Volume
- 76
- Issue
- 17
- Pages
- 1675-1682
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2548380697
- Cited by
- 90
- References
- 27
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 5 · 2023: 12 · 2022: 12 · 2021: 14 · 2020: 10 · 2019: 4 · 2018: 10 · 2017: 6
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- vortioxetine, major depressive disorder, cognitive impairment, antidepressants, serotonin transporter inhibition, executive function, attention, processing speed, learning and memory, recurrent depression, functional capacity, Digit Symbol Substitution Test, Rey Auditory Verbal Learning Test
- MeSH terms
- Vortioxetine, Animals, Antidepressive Agents, Cognition, Depression, Major Depressive Disorder, Humans, Piperazines, Sulfides, Anti-Anxiety Agents, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
